# Wave starts Phase 2a trial testing WVE-007 with weekly tirzepatide in obesity

Canonical page: https://technooptimist.io/stories/wave-starts-phase-2a-trial-testing-wve-007-with-weekly-tirzepatide-in-b1a29294
Date: 23 Sep 2026
About: [Wave Life Sciences](https://technooptimist.io/companies/wave-life-sciences.md) · [WVE-007](https://technooptimist.io/biotech/wve-007.md)
Original source: https://www.manilatimes.net/2026/09/23/tmt-newswire/globenewswire/wave-life-sciences-initiates-phase-2a-combination-trial-of-wve-007-galnac-sirna-with-tirzepatide-for-obesity/2431221

Wave Life Sciences announced on September 23, 2026 the start of a Phase 2a trial that combines its INHBE siRNA WVE-007 with weekly tirzepatide. The study tests two WVE-007 doses against a placebo group in adults with obesity, with and without type 2 diabetes. It is the company's test of whether its twice-yearly injection can add to the weight-loss effect of an existing GLP-1 drug.

## Key facts

- WVE-007 is tested at 240 mg and 400 mg, given with weekly tirzepatide.
- Population: adults with obesity (BMI 35 to 50), including people with type 2 diabetes.
- Randomization is 3:1 active to placebo.
- The release does not state how many participants will be enrolled.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.